Physician
Capitol Pain Institute, PA
Capitol Pain Institute, PA was paid $2.48M by Medicaid between Aug 2018 and Dec 2024, across 26 billing codes. Its largest line is 99214, doctor's office visit, returning patient (more involved) — 53% of everything it billed.
33Billing provider infoCAPITOL PAIN INSTITUTE, PA
AUSTIN, TX 78757
AUSTIN, TX 78757
33aNPI1548303985assigned 02/15/2007
33bProvider typeOrthopaedic Surgery Physician
28Total paid$2.48M
24GClaims72,677
24DCodes billed26
24AFirst – last monthAug 2018 – Dec 2024
Compared with peers
Next to other Orthopaedic Surgery Physician providers in Texas
Rank by total paid#1 of 105
Median peer was paid$11K
This provider vs. median222×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 1,572 | $25K | |
| 2019 | 9,204 | $277K | |
| 2020 | 8,051 | $217K | |
| 2021 | 10,571 | $300K | |
| 2022 | 14,558 | $490K | |
| 2023 | 15,887 | $614K | |
| 2024incomplete | 12,834 | $557K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 53% | 34,373 | 29,072 | $1.30M |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 15% | 11,075 | 9,022 | $367K |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 11% | 12,655 | 11,283 | $270K |
| 99204 | Doctor's office visit, new patient (more involved)Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity | 8.2% | 2,935 | 2,495 | $203K |
| J3300 | Injection, triamcinolone acetonide, preservative free, 1 mg | 4.4% | 1,537 | 1,260 | $109K |
| 99443 | 2.0% | 1,790 | 1,511 | $50K | |
| 99203 | Doctor's office visit, new patient (routine)Office or other outpatient visit for the evaluation and management of a new patient, low complexity | 1.6% | 883 | 773 | $40K |
| 64493 | 1.5% | 466 | 416 | $36K | |
| 62323 | <1% | 224 | 176 | $24K | |
| 64494 | <1% | 449 | 395 | $17K | |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed | <1% | 598 | 518 | $14K |
| 64483 | <1% | 52 | 51 | $6K |
14 more codes
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | <1% | 450 | $6K |
| 20610 | <1% | 167 | $6K | |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | <1% | 342 | $5K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 135 | $5K |
| 27096 | <1% | 18 | $4K | |
| 64635 | <1% | 24 | $4K | |
| 72275 | <1% | 68 | $2K | |
| 99442 | <1% | 237 | $2K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 1,867 | $2K |
| 64450 | <1% | 26 | $1K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 47 | $870.24 |
| 64636 | <1% | 12 | $482.16 | |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | <1% | 2,231 | $449.24 |
| 64495 | <1% | 16 | $257.56 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialSCHOCKET, SANDFORD (DIRECTOR)
| Provider | Location | Paid |
|---|---|---|
| Nura PLLC | Minneapolis, MN | $13.79M |
| Nura PLLC | Coon Rapids, MN | $6.24M |
| Nura Surgical Center LLC | Edina, MN | $582K |
| Matthew F Mccarty MD PLLC | Austin, TX | $242K |
| Pain and Aging Management LLC | Columbus, IN | $139K |
| Springs Rehabilitation Founder Holdings, PC | Colorado Springs, CO | $120K |
| Center for Specialty Surgery of Austin, LLC | Austin, TX | $0.00 |
| Water Leaf Surgery Center, LTD | Austin, TX | $0.00 |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.